ifnγ

TNF IFNγ-IN-1(TGA) 是 TNF 和 IFN-γ 的双重抑制剂。TNF IFNγ-IN-1 具有潜在的抗氧化和抗炎活性，可用于类似阿尔茨海默等的神经退行性疾病。

Anti-Mouse IFN gamma Antibody (R4-6A2) 为小鼠特异性抗IFNγ抗体，源自大鼠，属于IgG1kappa 类型。其同型对照为 RatIgG1kappa, Isotype Control。

Anti-Mouse IFN gamma Antibody (XMG1.2) 为一种IgG1kappa 类型的小鼠源抗体，专门针对IFNγ。该抗体的同型对照为RatIgG1kappa, Isotype Control，来源于大鼠。

Anti-Mouse IFN gamma Antibody为针对小鼠IFN gamma的IgG类免疫抑制性抗体，其宿主为Armenian Hamster。

IFN-α Receptor Recognition Peptide 1 is a peptide of IFN-α associated with receptor interactions.

StA-IFN-1 is an inhibitor of the interferon (IFN) induction pathway with an IC50 value of 4.1 μM in a GFP reporter assay for IFN induction similar to TPCA-1 , which specifically inhibits the IKKβ component of the IFN induction pathway. It does not show inhibitory activity in a GFP reporter assay for IFN signaling in which ruxolitinib , which is specific for the IFN signaling component JAK1, is active. StA-IFN-1 reduces the levels of IFN-β, but not ISG MxA, mRNA, suggesting that it is selective for the IFN induction pathway and not the IFN signaling pathway.

IFN-γAntagonist 1 (AYCRDGKIGPPKLDIRKEEKQI)，一种干扰素γ (IFN-γ) 拮抗剂，通过抑制IC50约为35 μM的IFN-γ诱导的HLR DR抗原在Colo 205细胞上的表达展现作用。该化合物在免疫调节领域具有潜在应用。

IFN-γAntagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate 作为一种干扰素 γ (IFN-γ) 拮抗剂，能够在 Colo 205 细胞中抑制 IFN-γ诱导的 HLR DR 抗原表达，其 IC50 值约为 35 μM，显示出在免疫调节中的潜在应用价值。

IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. It inhibits MVA-induced IFN-α responses by BM-pDCs (IC50: 2-8 μM).

Anti-IFNγ Antibody (B133.5) 为小鼠IgG1类嵌合抗体，针对人源IFNγ。该抗体的同型对照是 MouseIgG1kappa, Isotype Control。

SM-276001 是可口服的干扰素诱导剂，是选择性TLR7激动剂，可以诱导抗肿瘤免疫反应。

IFN alpha-IFNAR-IN-1 hydrochloride 是 IFN-α 和 IFNAR 相互作用的抑制剂。 IFN alpha-IFNAR-IN-1 hydrochloride 抑制 BM-pDCs 的 MVA 诱导的 IFN-α 反应，IC50 为 2-8 μM。

CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) 是一种氧化磷酸化 (OXPHOS) 抑制剂，线粒体质子载体解偶联剂。CCCP 抑制 STING 及其下游信号分子 TBK1 和 IRF3 的激活。

Bufexamac (Bufexamic acid) 是 HDAC6 和 HDAC10 的抑制剂，也是一种COX 抑制剂，用于释放 IFN-α，具有抗炎、镇痛和解热作用。

AX-024 hydrochloride (AX-024 HCl) 是一种细胞因子释放抑制剂，可强烈抑制 IL-6、TNFα、IFN-γ、IL-10 和 IL-17A 的产生。它是口服可利用的 TCR-Nck 相互作用抑制剂，可选择性地抑制 TCR 触发的 T 细胞活化。它通过靶向 SH3结构域调节细胞信号传导，具有低毒、高效和高选择性的特点。

Braylin has anti-inflammatory, antinociceptive and immunomodulatory effects, which possibly act through the glucocorticoid receptor activation and by inhibition of the transcriptional activity of NF-κB. Braylin is also a phosphodiesterase-4 inhibitor, it could represent an ideal prototype of glucocorticoid receptor ligand, able to induce synergic immunomodulatory effects.

Kazinol U may have therapeutic value in delaying pancreatic β-cell destruction in type 1 diabetes by blocking the NF-κB pathway in pancreatic β-cells reduces cell damage. Kazinol U shows estrogenic activity with ligand-activity of estrogen receptor, transcriptional activity of estrogen -responsive element-reporter genes, it may have beneficial effects in the treatment of menopausal symptoms.

(-)-Praeruptorin A has anti-inflammatory, anti-contractile and anti-hyperplasia activities, it exerts distinct relaxant effects on isolated rat aorta rings dependent on endothelium and nitric oxide synthesis;it also can significantly suppress airway inflammation and airway remodeling induced by ovalbumin challenge, and is a potential candidate for the treatment of asthma. (-)-Praeruptorin A resensitizes Pgp-mediated MDR (Pgp-MDR) cancer cells to cancer drugs.

(4S,5S)-(+)-Germacrone-4,5-epoxide inhibits certain subtypes of cytochrome P450 (CYP).

PD-1 PD-L1-IN-10 是一种口服有效的PD-1 PD-L1抑制剂 (IC50值为2.7 nM)，显示出抗肿瘤活性。

Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A c

Dehydrodiconiferyl alcohol （DHCA） 是一种从葫芦中分离出来的木脂素，通过作为雌激素受体激动剂抑制破骨细胞分化和卵巢切除术诱导的骨质流失。

IFNα-IN-1 (AJ2-18) 是一种 IFNα 抑制剂，用于抑制 IFN-α 的生成，并可应用于炎症研究。

(R)-Lisofylline ((R)-Lisophylline) 是溶血磷脂酸酰基转移酶的抑制剂 (IC50 = 0.6 µM)。 (R)-Lisofylline 可中断 IL-12 信号介导的 STAT4 激活，可用于治疗 1 型糖尿病和自身免疫性疾病的研究。